Interaction between Mediterranean diet and statins on mortality risk in patients with cardiovascular disease: Prospective findings from the Moli-sani Study

Publication date: August 2019Source: Nutrition, Metabolism and Cardiovascular Diseases, Volume 29, Issue 8Author(s): Marialaura Bonaccio, Augusto Di Castelnuovo, Simona Costanzo, Mariarosaria Persichillo, Amalia De Curtis, Chiara Cerletti, Maria Benedetta Donati, Giovanni De Gaetano, Licia Iacoviello
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research

Related Links:

STATINS can prevent liver cancer, according to a new study.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
MONDAY, Aug. 19, 2019 (American Heart Association News) -- Women are less likely than men to be treated with cholesterol-lowering statins– or get them prescribed at guideline-recommended intensity levels when they do, according to a new study...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
The administration of geranylgeranyl pyrophosphate (GGPP) (or its precursor, geranylgeraniol) has been shown by several in vitro studies to be capable of abrogating statin-induced myotoxicity. Nonetheless, the potential of GGPP repletion to prevent statin-associated muscle symptoms (SAMS) in vivo is yet to be investigated. Therefore, this study aimed to evaluate the ability of geranylgeraniol (GGOH) to prevent SAMS in rodents. Female Wistar rats (12 weeks of age) were randomised to one of four treatment groups: control, control with GGOH, simvastatin or simvastatin with GGOH.
Source: Translational Research - Category: Research Authors: Source Type: research
CONCLUSION: ATV inhibited ROS generation and activated IL-1 β/IL-6 secretion in PBMNC of diabetes patients. Its effect was not affected by the hyperglymemia. PMID: 31416412 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. Its prevalence is increasing because of obesity, metabolic syndrome or Type 2 Diabetes Mellitus (T2DM). NAFLD can cause liver inflammation and progress to Non-Alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis or Hepatocellular Cancer (HCC). Nevertheless, Cardiovascular Disease (CVD) is the most common cause of morbidity and mortality in NAFLD/NASH patients. Current guidelines suggest the use of p...
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Vasc Pharmacol Source Type: research
Authors: Hou C, Zheng B, Wang XG, Zhang B, Shi QP, Chen M Abstract Previous studies have reported that short-term statin loading effectively protects statin-naive patients with mild renal insufficiency from contrast-induced acute kidney injury (CI-AKI). The aim of the present study was to determine whether patients with more advanced chronic kidney disease (CKD) and long-term statin therapy also benefit from high-loading statin pretreatment. A total of 256 consecutive patients with moderate-to-severe CKD receiving long-term statin therapy and undergoing percutaneous coronary intervention (PCI) or coronary artery an...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
In 2012, Medicare incorporated medication adherence targeting oral antidiabetic medications, renin-angiotensin system (RAS) antagonists, and statins as highly weighted components in its Star Ratings Program. In the same year, health plans began receiving quality bonus payments for higher star ratings.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
Conclusions: The ACO cohort with statin use exhibited the lower risk of hepatic, renal, and heart failure than any other cohort, regardless of age, sex, comorbidities, or ICS or OS use. Regarding the combined use of statins and ICS, the risks of hepatic failure were lower. For the combined use of statins and OS, the hepatic, renal and heart failure were less frequent.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
We report a case of statin induced necrotizing autoimmune myopathy (SINAM), a rare variant of statin-induced myopathy.A 64-year-old gentleman on atorvastatin presented with muscle weakness, initial laboratory results showed elevated liver function tests, a creatine phosphokinase (CPK) of 8200 IU/L and positive urine myoglobin. Despite discontinuing atorvastatin, his CPK remained persistently elevated. Muscle biopsy was consistent with necrotizing myopathy. Anti - HMG CoA reductase antibody was strongly positive. Steroids followed by intravenous immunoglobulin were given. His muscle weakness, CPK, and liver functions gradua...
Source: Journal of the Saudi Heart Association - Category: Cardiology Source Type: research
Authors: Katsiki N, Kotsa K, Athyros VG, Mikhailidis DP PMID: 31411083 [PubMed - as supplied by publisher]
Source: Expert Review of Cardiovascular Therapy - Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Diets | Heart | Nutrition | Statin Therapy | Study